MyFinsight
Home
Blog
About
Proceeds from the private
placement issuance of...
$26,800,000
Net cash assumed in
the acquisition of...
$5,282,000
Net proceeds from
sale of common stock
$849,716
(-72.83%↓ Y/Y)
Net cash provided by
financing activities
$25,208,716
(371.27%↑ Y/Y)
Net cash provided by
investing activities
$5,132,000
(3321.33%↑ Y/Y)
Canceled cashflow
$2,441,000
Net increase in cash
and cash...
$24,128,117
(1014.74%↑ Y/Y)
Canceled cashflow
$6,362,599
Issuance costs from the
private placement...
$2,441,000
Acquired in process
research and development
-$46,185,000
Loss on
extinguishment of azora...
-$6,054,000
Financing expense related
to milestone...
$2,067,000
Accounts payable
$1,736,640
(312.52%↑ Y/Y)
Change in value of
equity method...
-$181,030
(30.86%↑ Y/Y)
Equity-based compensation
$137,100
(-62.00%↓ Y/Y)
Prepaid expenses and
other current assets
-$95,182
(34.17%↑ Y/Y)
Net cash used in
operating activities
-$6,362,599
(-90.80%↓ Y/Y)
Canceled cashflow
$56,455,952
Net loss
-$51,989,608
Change in fair value of
milestone warrant rights...
-$8,280,000
Accrued expenses
-$2,548,802
(-1753.04%↓ Y/Y)
Back
Back
Cash Flow
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)
source: myfinsight.com